Oxeltis
Private Company
Funding information not available
Overview
Oxeltis operates as a specialized contract research organization (CRO) focused on high-value medicinal and fine organic chemistry services for drug discovery. The company leverages its core expertise in complex synthetic chemistry, particularly nucleos(t)ides and heterocycles, to support client programs from early-stage research through lead optimization. Its strategic partnership with Molecular Forecaster integrates computational design with wet-lab synthesis, enhancing its service offering. Led by an experienced management team with strong pharma backgrounds, Oxeltis is positioned as a niche player supporting the growing outsourced R&D market.
Technology Platform
Integrated medicinal chemistry services platform with core expertise in nucleos(t)ide, heterocyclic, macrocyclic, and carbohydrate synthesis. Enhanced by a strategic partnership with Molecular Forecaster Inc. for integrated computational drug design (CADD) and wet-lab synthesis.
Opportunities
Risk Factors
Competitive Landscape
Competes within the fragmented drug discovery CRO market, facing competition from large global players (e.g., Charles River, Evotec) with broad integrated services and smaller niche chemistry providers. Differentiation is based on deep, specialized expertise in complex synthesis areas like nucleos(t)ides and the unique integrated computational/wet-lab offering with its partner MFI.